

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

NOVADEL PHARMA INC
Form 8-K
December 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) DECEMBER 7, 2004

NOVADEL PHARMA INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

| | | |
|---------------------------------------------------|-----------------------|-----------------------------------------|
| DELAWARE | 000-23399 | 22-2407152 |
| (STATE OR OTHER JURISDICTION OF INCORPORATION) | (COMMISSION FILE NO.) | (I.R.S. EMPLOYER IDENTIFICATION NO.) |

25 MINNEAKONING ROAD
FLEMINGTON, NEW JERSEY 08822
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

(908) 782-3431
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

N/A
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

ITEM 5.03 AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

On December 7, 2004, the Company's Board of Directors approved an amendment to the Company's By-laws. The amendment allows the Board of Directors to designate any date and time as the date and time of the Company's annual meeting of shareholders. Prior to the amendment, the By-laws provided that the Company's annual meeting of shareholders be held on a date set by the Board of Directors within five months after the close of the fiscal year of the Company (Article II, Section 2).

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

3.2. By-Laws of NovaDel Pharma Inc., as amended through December 7, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVADEL PHARMA INC.

By: /s/ Gary A. Shangold

Name: Gary A. Shangold, Ph.D.

Title: President and Chief Executive Officer